PER

PERCHERON FPO [PER]
Percheron Therapeutics Limited engages in the research and development of antisense pharmaceuticals for cancer and rare diseases in Australia. Its products pipeline includes HMBD-002, a recombinant humanised monoclonal IgG4 antibody, which completed phase I clinical trial to treat to human v-domain immunoglobulin suppressor of T-cell activation (VISTA). The company was formerly known as Antisense Therapeutics Limited and changed its name to Percheron Therapeutics Limited in December 2023. Percheron Therapeutics Limited was incorporated in 2000 and is based in Melbourne, Australia.
Healthcare · ASX Small Cap
$0.0050 +0.0%

Updated 3 Sep 2026 · Signals refresh every scan

Appeared in 2 consecutive scansFirst seen: 2026-02-25
Get alerts when PER triggers a new signal
Free watchlist with daily scans for 2,200+ ASX stocks
Track PER — Free

Active Signals

Bullish Signals

  • MACD momentum is losing steam
  • Volume surging at 3.1x normal while price falls — heavy selling pressure
  • Beating the Small Ords index — relative strength of 1.70, so it's outpacing the pack
  • Volatility is contracting — like a spring being compressed, breakouts often follow
  • Low cash runway (3 quarters) - dilution risk
  • Moderate P/S ratio (9.0x)
  • Revenue in sharp decline (-54%)
  • Micro-cap ($5-20M) - high risk
  • Capital raise activity (3 events)
  • Dilution velocity warning (3 raises recently)
  • Sentiment is mixed — no strong consensus either way
  • This one has been in freefall — down 57% over the past year
  • The bigger volume days are the up days — volume-weighted momentum is positive (2.11%/day)
  • Elevated dilution risk (3 recent capital raises)
  • Penny stock risk ($0.005)
  • RBA hiking (-3pts)

Risk Signals

  • Below the 200-day average — the long-term trend is still working against it
  • Piotroski F-Score weak (3/9, low-confidence approx)
  • Not enough chatter to gauge sentiment — defaulting to neutral
  • Revenue declining at -54% — the top line is shrinking
Ask Scout AI about PER
"What's driving PER today?" "How does PER compare to peers?" "Key risks for PER?"
3 free messages/day · Unlimited with Pro

Recent Catalysts

NONE Percheron Therapeutics Limited Corporate Presentation
NONE Proposed issue of securities - PER
NONE Proposed issue of securities - PER
MEDIUM Percheron raises $2.3m to fully fund clinical trial in AML
Announcement tone +3pts

Recent ASX Announcements

2026-09-01 Percheron Therapeutics Limited Corporate Presentation
2026-08-31 Proposed issue of securities - PER
2026-08-31 Proposed issue of securities - PER
2026-08-31 Proposed issue of securities - PER
2026-08-31 Percheron raises $2.3m to fully fund clinical trial in AML PRICE SENSITIVE

Key Metrics

$7.6M
Market Cap
5.6M
Avg Volume
3.1x
Vol Ratio
$0.00 — $0.01
52-Week Range
N/A
Short Interest
N/A
Cash Runway
-54.7%
ROE
N/A
Profit Margin

CANSLIM Analysis

FactorRatingDetail
CCurrent EPSfailEPS Growth: 0%
AAnnual EarningsfailCAGR: 0%
NNew Highs / Catalystsneutral
SSupply & DemandneutralFloat: 78%
LLeader vs LaggardpassRS: 12
IInstitutional SponsorshipweakInst: 3%
MMarket DirectionneutralNeutral

Sector: Healthcare

113 tickers in this sector

View all Healthcare signals →Browse all ASX tickers A–Z →
Related Tickers
REG -27.0%CAN +25.0%BIT -20.0%MEM +20.0%CMP -14.6%
Compare:PER vs REGPER vs CANPER vs BIT
Scout Pro — Deeper Analysis for PER
Try Pro free for 30 days
Share this analysis

Track PER and 2,200+ ASX stocks

Get free access to Scout's AI-powered dashboard with daily scans, watchlist alerts, and exit management for every ASX small cap.

Open Dashboard — Free Free Screener
No credit card required